

# Medical Policy



## Title: Chelation Therapy for Off-Label Uses

<b>Professional / Institutional</b>
Original Effective Date: October 29, 2009
Latest Review Date: April 14, 2026
Current Effective Date: August 19, 2016

**State and Federal mandates and health plan member contract language, including specific provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. To verify a member's benefits, contact [Blue Cross and Blue Shield of Kansas Customer Service](#).**

**The BCBSKS Medical Policies contained herein are for informational purposes and apply only to members who have health insurance through BCBSKS or who are covered by a self-insured group plan administered by BCBSKS. Medical Policy for FEP members is subject to FEP medical policy which may differ from BCBSKS Medical Policy.**

**The medical policies do not constitute medical advice or medical care. Treating health care providers are independent contractors and are neither employees nor agents of Blue Cross and Blue Shield of Kansas and are solely responsible for diagnosis, treatment and medical advice.**

**If your patient is covered under a different Blue Cross and Blue Shield plan, please refer to the Medical Policies of that plan.**

Populations	Interventions	Comparators	Outcomes
Individuals: • With Alzheimer disease,	Interventions of interest are: • Chelation therapy	Comparators of interest are: • Standard medical care	Relevant outcomes include: • Symptoms • Change in disease status • Morbid events • Functional outcomes • Health status measures • Quality of life • Treatment-related morbidity
Individuals: • With cardiovascular disease	Interventions of interest are: • Chelation therapy	Comparators of interest are: • Standard medical care	Relevant outcomes include: • Symptoms • Change in disease status • Morbid events • Functional outcomes

Populations	Interventions	Comparators	Outcomes
			<ul style="list-style-type: none"> <li>• Health status measures</li> <li>• Quality of life</li> <li>• Treatment-related morbidity</li> </ul>
Individuals: <ul style="list-style-type: none"> <li>• With autism spectrum disorder</li> </ul>	Interventions of interest are: <ul style="list-style-type: none"> <li>• Chelation therapy</li> </ul>	Comparators of interest are: <ul style="list-style-type: none"> <li>• Standard medical care</li> </ul>	Relevant outcomes include: <ul style="list-style-type: none"> <li>• Symptoms</li> <li>• Change in disease status</li> <li>• Morbid events</li> <li>• Functional outcomes</li> <li>• Health status measures</li> <li>• Quality of life</li> <li>• Treatment-related morbidity</li> </ul>
Individuals: <ul style="list-style-type: none"> <li>• With diabetes</li> </ul>	Interventions of interest are: <ul style="list-style-type: none"> <li>• Chelation therapy</li> </ul>	Comparators of interest are: <ul style="list-style-type: none"> <li>• Standard medical care</li> </ul>	Relevant outcomes include: <ul style="list-style-type: none"> <li>• Symptoms</li> <li>• Change in disease status</li> <li>• Morbid events</li> <li>• Functional outcomes</li> <li>• Health status measures</li> <li>• Quality of life</li> <li>• Treatment-related morbidity</li> </ul>
Individuals: <ul style="list-style-type: none"> <li>• With multiple sclerosis</li> </ul>	Interventions of interest are: <ul style="list-style-type: none"> <li>• Chelation therapy</li> </ul>	Comparators of interest are: <ul style="list-style-type: none"> <li>• Standard medical care</li> </ul>	Relevant outcomes include: <ul style="list-style-type: none"> <li>• Symptoms</li> <li>• Change in disease status</li> <li>• Morbid events</li> <li>• Functional outcomes</li> <li>• Health status measures</li> <li>• Quality of life</li> <li>• Treatment-related morbidity</li> </ul>
Individuals: <ul style="list-style-type: none"> <li>• With arthritis</li> </ul>	Interventions of interest are: <ul style="list-style-type: none"> <li>• Chelation therapy</li> </ul>	Comparators of interest are: <ul style="list-style-type: none"> <li>• Standard medical care</li> </ul>	Relevant outcomes include: <ul style="list-style-type: none"> <li>• Symptoms</li> <li>• Change in disease status</li> <li>• Morbid events</li> <li>• Functional outcomes</li> <li>• Health status measures</li> <li>• Quality of life</li> <li>• Treatment-related morbidity</li> </ul>

**DESCRIPTION**

Chelation therapy, an established treatment for heavy metal toxicities and transfusional hemosiderosis, has been investigated for a variety of off-label applications, such as treatment of atherosclerosis, Alzheimer disease, and autism. This evidence review does not address indications for chelation therapy approved by the U.S. Food and Drug Administration. Instead, it addresses off-label indications, including Alzheimer disease, cardiovascular disease, autism spectrum disorder, diabetes, multiple sclerosis, and arthritis.

**OBJECTIVE**

The objective of this evidence review is to determine whether chelation therapy, when used as a treatment for various off-label applications such as Alzheimer disease, cardiovascular disease, autism spectrum disorder, diabetes, multiple sclerosis, and arthritis, improves the net health outcome.

**BACKGROUND****Chelation Therapy**

Chelation therapy is an established treatment for the removal of metal toxins by converting them to a chemically inert form that can be excreted in the urine. Chelation therapy comprises intravenous or oral administration of chelating agents that remove metal ions such as lead, aluminum, mercury, arsenic, zinc, iron, copper, and calcium from the body (see Appendix Table 1). Specific chelating agents are used for particular heavy metal toxicities. For example, deferoxamine is used for patients with iron toxicity, and calcium-ethylenediaminetetraacetic acid (EDTA) is used for patients with lead poisoning. Disodium-EDTA is not recommended for acute lead poisoning due to the increased risk of death from hypocalcemia.<sup>1</sup>

Another class of chelating agents, called metal protein attenuating compounds (MPACs), is under investigation for the treatment of Alzheimer disease, which is associated with the disequilibrium of cerebral metals. Unlike traditional systemic chelators that bind and remove metals from tissues systemically, MPACs have subtle effects on metal homeostasis and abnormal metal interactions. In animal models of Alzheimer disease, MPACs promote the solubilization and clearance of  $\beta$ -amyloid by binding its metal-ion complex and also inhibit redox reactions that generate neurotoxic free radicals. Therefore, MPACs interrupt 2 putative pathogenic processes of Alzheimer disease. However, no MPACs have received FDA approval for treating Alzheimer disease.

Chelation therapy also has been considered as a treatment for other indications, including atherosclerosis and autism spectrum disorder. For example, EDTA chelation therapy has been proposed in patients with atherosclerosis as a method of decreasing obstruction in the arteries.

**REGULATORY STATUS**

In 1953, EDTA (Versenate) was approved by the FDA for lowering blood lead levels among both pediatric and adult patients with lead poisoning. In 1991, succimer (Chemet) was approved by the FDA for the treatment of lead poisoning in pediatric patients only. The

FDA approved disodium-EDTA for use in selected patients with hypercalcemia and use in patients with heart rhythm problems due to intoxication with digitalis. In 2008, the FDA withdrew approval of disodium-EDTA due to safety concerns and recommended that other forms of chelation therapy be used.<sup>2</sup>

Several iron-chelating agents are FDA approved:

- In 1968, deferoxamine (Desferal®; Novartis) was approved by the FDA for subcutaneous, intramuscular, or intravenous injections to treat acute iron intoxication and chronic iron overload due to transfusion-dependent anemia. Several generic forms of deferoxamine have been approved by the FDA.
- In 2005, deferasirox (Exjade®; Novartis) was approved by the FDA, is available as a tablet for oral suspension, and is indicated for the treatment of chronic iron overload due to blood transfusions in patients age 2 years and older. Under the accelerated approval program, the FDA expanded the indications for deferasirox in 2013 to include treatment of patients age 10 years and older with chronic iron overload due to non-transfusion-dependent thalassemia syndromes and specific liver iron concentration and serum ferritin levels. A generic version of deferasirox tablet for oral suspension has also been approved by the FDA. In 2015, an oral tablet formulation for deferasirox (Jadenu®) was approved by the FDA. All formulations of deferasirox carry a boxed warning because it may cause serious and fatal renal toxicity and failure, hepatic toxicity and failure, and gastrointestinal hemorrhage. As a result, treatment with deferasirox requires close patient monitoring, including laboratory tests of renal and hepatic function.
- In 2011, the iron chelator deferiprone (Ferriprox®) was approved by the FDA for treatment of patients with transfusional overload due to thalassemia syndromes when another chelation therapy is inadequate. Deferiprone is available in tablet and oral solution. Ferriprox carries a boxed warning because it can cause agranulocytosis, which can lead to serious infections and death. As a result, absolute neutrophil count should be monitored before and during treatment.

In a June 2014 warning to consumers, the FDA advised that FDA-approved chelating agents would be available by prescription only. There are no FDA approved over-the-counter chelation products.

## POLICY

- A. Off-label applications of chelation therapy (see Policy Guidelines section for uses approved by the U.S. Food and Drug Administration) are considered **experimental / investigational**, including, but not limited to:
1. Alzheimer's disease
  2. atherosclerosis (e.g., coronary artery disease, secondary prevention in individuals with myocardial infarction, or peripheral vascular disease)
  3. autism
  4. diabetes
  5. multiple sclerosis
  6. arthritis (includes rheumatoid arthritis)

## POLICY GUIDELINES

- A. A number of indications for chelation therapy have received U.S. Food and Drug Administration (FDA) approval and for which chelation therapy is considered standard of care treatment. These indications include:
1. extreme conditions of metal toxicity
  2. treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) or due to non-transfusion-dependent thalassemia (NTDT)
  3. Wilson disease (hepatolenticular degeneration)
  4. lead poisoning
  5. control of ventricular arrhythmias or heart block associated with digitalis toxicity
  6. emergency treatment of hypercalcemia
- B. For the last 2 bullet points, most individuals should be treated with other modalities. Digitalis toxicity is currently treated in most individuals with Fab monoclonal antibodies. FDA removed the approval for NaEDTA as chelation therapy due to safety concerns and recommended that other chelators be used. NaEDTA was the most common chelation agent used to treat digitalis toxicity and hypercalcemia.

**Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.**

## RATIONALE

This evidence review was created using searches of the PubMed database. The most recent literature update was performed through December 15, 2025.

Evidence reviews assess the clinical evidence to determine whether the use of technology improves the net health outcome. Broadly defined, health outcomes are the length of life, quality of life, and ability to function, including benefits and harms. Every clinical condition has specific outcomes that are important to patients and to managing the course of that condition. Validated outcome measures are necessary to ascertain whether a condition improves or worsens; and

whether the magnitude of that change is clinically significant. The net health outcome is a balance of benefits and harms.

To assess whether the evidence is sufficient to draw conclusions about the net health outcome of technology, 2 domains are examined: the relevance, and quality and credibility. To be relevant, studies must represent 1 or more intended clinical use of the technology in the intended population and compare an effective and appropriate alternative at a comparable intensity. For some conditions, the alternative will be supportive care or surveillance. The quality and credibility of the evidence depend on study design and conduct, minimizing bias and confounding that can generate incorrect findings. The randomized controlled trial (RCT) is preferred to assess efficacy; however, in some circumstances, nonrandomized studies may be adequate. Randomized controlled trials are rarely large enough or long enough to capture less common adverse events and long-term effects. Other types of studies can be used for these purposes and to assess generalizability to broader clinical populations and settings of clinical practice. The following is a summary of the key literature to date.

## **ALZHEIMER DISEASE**

### **Clinical Context and Therapy Purpose**

The purpose of chelation therapy is to provide a treatment option that is an alternative to or an improvement on existing therapies for individuals with Alzheimer disease.

The following PICO was used to select literature to inform this review.

### ***Populations***

The population of interest is individuals with Alzheimer disease.

### ***Interventions***

The intervention of interest is chelation therapy.

### ***Comparators***

The comparator of interest is standard medical care without chelation therapy.

### ***Outcomes***

The outcomes of interest are symptoms, change in disease status, morbid events, functional outcomes, health status measures, quality of life, and treatment-related morbidity.

### **Study Selection Criteria**

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Studies with duplicative or overlapping populations were excluded.

## **REVIEW OF EVIDENCE**

### Systematic Review

A Cochrane review (2008) evaluated metal protein attenuating compounds for treating Alzheimer disease.<sup>3</sup> Reviewers identified a placebo-controlled randomized trial. This study by Ritchie et al (2003) assessed patients treated with PBT1, a metal protein attenuating compound also known as clioquinol, which is an antifungal medication that crosses the blood-brain barrier.<sup>4</sup> The U.S. Food and Drug Administration (FDA) withdrew clioquinol for oral use from the market in 1970 because of its association with subacute myelo-optic neuropathy. Ritchie et al (2013) administered oral clioquinol to 16 patients with Alzheimer disease in doses increasing to 375 mg twice daily and compared this group with 16 matched controls who received placebo. At 36 weeks, there was no statistically significant between-group difference in cognition measured by the Alzheimer Disease Assessment Scale–Cognitive. One patient in the treatment group developed impaired visual acuity and color vision during weeks 31 to 36 of treatment with clioquinol 375 mg twice daily. Her symptoms resolved on treatment cessation. Updates of this Cochrane review (2012 and 2014) included trials through January 2012.<sup>5,6</sup> Only the Lannfelt et al (2008) trial (discussed next) was identified.<sup>5</sup>

Further study of PBT1 was abandoned in favor of a successor compound, PBT2. Lannfelt et al (2008) completed a double-blind, placebo-controlled randomized trial of 78 patients with Alzheimer disease who were treated for 12 weeks with PBT2 50 mg (n=20), PBT2 250 mg (n=29), or placebo (n=29).<sup>7</sup> There was no statistically significant difference in Alzheimer Disease Assessment Scale–Cognitive or Mini-Mental Status Examination scores among groups in this short-term study. The most common adverse event was headache. Two serious adverse events (urosepsis, transient ischemic event) were reported in the placebo arm.

In 2025, Ayton and colleagues published the results of a phase 2, double-masked RCT of deferiprone 15 mg/kg twice daily versus placebo conducted in 9 sites across Australia.<sup>8</sup> Study participants were 54 years or older with amyloid-confirmed mild cognitive impairment or early Alzheimer disease with a Mini-Mental State Examination score of 20 or higher. Randomization was 2:1, with 53 assigned to deferiprone and 28 to placebo. The primary outcome measure was a composite cognitive measure assessed at baseline, 6 months, and 12 months. In an intention-to-treat analysis, the deferiprone group showed accelerated cognitive decline on the neuropsychological test battery (change in composite z score for deferiprone, -80.0 [95% confidence interval (CI), -0.98 to -0.62]; for placebo, -0.30 [95% CI, -0.54 to -0.06]). The accelerated decline in the deferiprone group was driven by a decrease in executive function tests. Quantitative susceptibility mapping (QSM) magnetic resonance imaging (MRI) confirmed that use of deferiprone decreased iron concentrations in the hippocampus compared to placebo. The investigators concluded that these results suggest that iron chelation with deferiprone may be detrimental to patients with early Alzheimer disease.

### Section Summary: Alzheimer Disease

There is insufficient evidence on the safety and efficacy of chelation therapy for treating patients with Alzheimer disease. The few published RCTs did not find that chelation was superior to placebo for improving health outcomes. One RCT, published in 2025, found that iron chelation with deferiprone accelerated the rate of cognitive decline in early Alzheimer disease.

## CARDIOVASCULAR DISEASE

**Clinical Context and Therapy Purpose**

The purpose of chelation therapy is to provide a treatment option that is an alternative to or an improvement on existing therapies for individuals with cardiovascular disease.

The following PICO was used to select literature to inform this review.

**Populations**

The population of interest is individuals with cardiovascular disease.

**Interventions**

The intervention of interest is chelation therapy.

**Comparators**

The comparator of interest is standard medical care without chelation therapy.

**Outcomes**

The outcomes of interest are symptoms, change in disease status, morbid events, functional outcomes, health status measures, quality of life, and treatment-related morbidity.

**Study Selection Criteria**

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Studies with duplicative or overlapping populations were excluded.

**REVIEW OF EVIDENCE****Systematic Review**

Ravalli et al (2022) published a systematic review and meta-analysis of 24 trials, including 4 RCTs, that evaluated the use of ethylenediaminetetraacetic acid (EDTA) in patients with cardiovascular disease.<sup>9</sup> Ankle-brachial index was the only outcome reported in at least 3 studies and included in meta-analysis (Table 3). Overall, 17 studies reported improved outcomes with EDTA, 5 reported no significant effect, and 2 reported no qualitative benefit. The studies included in this meta-analysis are limited by the lack of clinical outcomes, the variety of infusion methods, limited sample sizes, and minimal follow-up time.

Villarruz-Sulit et al (2020) published a Cochrane review that evaluated EDTA chelation therapy for treating patients with atherosclerotic cardiovascular disease.<sup>10</sup> Five placebo-controlled trials were included (N=1993 ; range, 10 to 1708); 3 studies included patients with peripheral vascular disease and 2 studies included patients with coronary artery disease, with one specifically recruiting patients with a previous myocardial infarction. One study had a high risk of bias, since investigators broke randomization partway through the trial, but all other trials were rated as moderate to low. A meta-analysis of included studies found no difference between chelation therapy and placebo with regard to all-cause mortality (n=1792, 2 studies; risk ratio [RR], 0.97;

95% CI, 0.73 to 1.28), cardiovascular death (n=1708, 1 study; RR, 1.02; 95% CI, 0.70 to 1.48), myocardial infarction (n=1792, 2 studies; RR, 0.81; 95% CI, 0.57 to 1.14), angina (n=1792, 2 studies; RR, 0.95; 95% CI, 0.55 to 1.67), or coronary revascularization (n=1792, 2 studies; RR, 0.46; 95% CI, 0.07 to 3.25). Cochrane reviewers found that the evidence was insufficient to support conclusions about the efficacy of chelation therapy for treating atherosclerosis. Additional RCTs reporting health outcomes like mortality and cerebrovascular events were suggested.

**Table 1. Comparison of Randomized Controlled Trials Included in Systematic Reviews and Meta-analyses**

Study	Ravalli et al (2022) <sup>9</sup> ,	Villarruz-Sulit et al (2020) <sup>10</sup> ,
Lamas et al (2013)	●	●
Knudston et al (2002)	●	●
van Rij et al (1994)	●	●
Guldager et al (1992)	●	●
Olszewer et al (1990)		●

**Table 2. Systematic Review and Meta-analysis Characteristics**

Study	Dates	Trials	Participants	N (Range)	Design	Duration
Ravalli et al (2022) <sup>9</sup> ,	To October 2021	24 (4 RCTs, 15 prospective before/after trials, 5 retrospective studies)	Patients treated with EDTA for atherosclerotic cardiovascular disease	5501 (4 to 2870)	RCT	NR
Villarruz-Sulit et al (2020) <sup>10</sup> ,	To August 2019	5 RCTs	Patients treated with EDTA for atherosclerotic cardiovascular disease	1993 (10 to 1708)	RCT	6 months to 5 years

EDTA: ethylenediaminetetraacetic acid; NR: not reported; RCT: randomized controlled trial.

**Table 3. Systematic Review and Meta-analysis Results**

Study	All-cause mortality	CHD Deaths	MI	Revascularization	Stroke	ABI
Ravalli et al (2022) <sup>9</sup> ,						
Total N	1792	1708	1792	1792	1867	181
Risk ratio (95% CI)	0.97 (0.73 to 1.28)	1.02 (0.7 to 1.48)	0.81 (0.57 to 1.14)	0.46 (0.07 to 3.25)	0.88 (0.40 to 1.92)	0.02 (-0.03 to 0.06)

Study	All-cause mortality	CHD Deaths	MI	Revascularization	Stroke	ABI
$I^2$ (p)	NA	NA	0% (.85)	56% (.13)	0% (.43)	0% (.59)
Villarruz-Sulit et al (2020) <sup>10</sup> ,						
Total N						173
Mean difference (95% CI)						0.08 (0.06 to 0.09)
$I^2$ (p)						94% (NR)

ABI: ankle-brachial index; CHD: coronary heart disease; CI: confidence interval; MI: myocardial infarction; NA: not applicable; NR: not reported.

### Randomized Controlled Trial

The largest RCT included in the meta-analyses is the multicenter, 2 × 2 factorial, double-blind, randomized Trial to Assess Chelation Therapy (TACT), which was published by Lamas et al in 2013.<sup>11</sup> TACT included 1708 patients, age 50 years or older, who had a history of myocardial infarction at least 6 weeks before enrollment and a serum creatinine level of 2.0 mg/dL or less. Patients were randomized to 40 intravenous infusions of disodium EDTA (n=839) or placebo (n=869). Patients also received oral high-dose vitamin plus mineral therapy or placebo. The first 30 infusions were given weekly, and the remaining 10 infusions were given 2 to 8 weeks apart. The primary endpoint was a composite outcome that included death from any cause, reinfarction, stroke, coronary revascularization, or hospitalization for angina at 5 years. The threshold for statistical significance was adjusted for multiple interim analyses to a p-value of .036. A total of 361 (43%) patients in the chelation group and 464 (57%) patients in the placebo group discontinued treatment, withdrew consent, or were lost to follow-up. Kaplan-Meier 5-year estimates for the primary endpoint was 33% (95% CI, 29% to 37%) in the chelation group and 39% (95% CI, 35% to 42%) in the control group, a statistically significant difference (p=.035). The most common individual clinical endpoint was coronary revascularization, which occurred in 130 (16%) of 839 patients in the chelation group and 157 (18%) of 869 patients in the control group (p=.08). The next most frequent endpoint was death, which occurred in 87 (10%) patients in the chelation group and 93 (11%) patients in the placebo group (p=.64). No individual component of the primary outcome differed statistically between groups; however, the trial was not powered to detect differences in individual components. Four severe adverse events definitely or possibly related to study therapy occurred, 2 each in the treatment and control groups, including 1 death in each. Quality of life outcomes (reported in 2014) did not differ between groups at 2-year follow-up.<sup>12</sup>

A 2014 follow-up publication reported results for the 4 treatment groups in the 2 × 2 factorial design (double-active group [disodium-EDTA infusions with oral high-dose vitamins; n=421 patients], active infusions with placebo vitamins [n=418 patients], placebo infusions with active vitamins [n=432 patients], or double placebo [n=437 patients]).<sup>13</sup> The proportion of patients who discontinued treatment, withdrew consent, or were lost to follow-up per treatment group were not reported. Five-year Kaplan-Meier estimates for the primary composite endpoint were 32%, 34%, 37%, and 40%, respectively. The reduction in primary endpoint by double-active treatment compared with double placebo was statistically significant (hazard ratio [HR], 0.74;

95% CI, 0.57 to 0.95). In 633 patients with diabetes (>36% of each treatment group), the primary endpoint reduction in the double-active group compared with the double placebo group was more pronounced (HR, 0.49; 95% CI, 0.33 to 0.75). A post-hoc analysis showed that chelation was associated with a lower risk of the primary endpoint compared with placebo in patients with post anterior myocardial infarction (n=674; HR, 0.63; 95% CI, 0.47 to 0.86; p=.003); however, this effect was not seen in post non-anterior myocardial infarction.<sup>14</sup>

The trial was limited by the high number of withdrawals, with differential withdrawals between groups. The primary endpoint included components of varying clinical significance, and the largest difference between groups was for revascularization events. The primary endpoint barely met the significance threshold; if more patients had remained in the study and experienced events, results could have differed. Moreover, as noted in an editorial accompanying the original (2013) publication, 60% of patients were enrolled at centers described as complementary and alternative medicine sites, and this may have resulted in the selection of a population not generalizable to that seen in general clinical care.<sup>15</sup> Editorialists commenting on the subsequent (2014) publication suggested that further research would be warranted to replicate the findings.<sup>16</sup> This secondary analysis had the same limitations as the parent study previously described (ie, high and differential withdrawal, heterogeneous composite endpoint). Additionally, because diabetes was not a stratification factor in TACT, results of this subgroup analysis are preliminary and require replication.

The TACT2 study replicated the design of the original TACT study evaluating 40 weekly infusions of EDTA-based chelation in patients with prior myocardial infarction and diabetes.<sup>17</sup> Enrollment was complete in December 2020 and treatment was complete in December 2021. In August 2024, Lamas et al published outcomes from TACT2 (N=1000).<sup>18</sup> TACT2 failed to replicate the findings from the original TACT trial. Primary composite outcome events were observed in 172 (35.6%) of participants receiving at least one active chelation infusion compared to 170 (35.7%) receiving at least one placebo infusion (adjusted HR, 0.93; 95% CI, 0.76 to 1.16 ; p=.53). The Kaplan-Meier 5-year cumulative incidence estimates for the primary endpoint were 45.8% (95% CI, 39.9% to 51.5%) and 46.5% (95% CI, 39.7% to 53.0%) for chelation and placebo groups, respectively. There were no statistically significant differences in individual cardiovascular event components of the composite outcome. The adjusted HR for death from any cause was 0.96 (95% CI, 0.71 to 1.30). Blood lead levels dropped by 61% in participants receiving active chelation. All 40 infusions were received in 67% of participants assigned to active chelation and 67% assigned to placebo. Consent was withdrawn during follow-up for 60 (6%) participants (22 chelation and 38 placebo) and 62 (6%) participants were lost to follow-up (35 chelation and 27 placebo). Prespecified sensitivity analyses did not indicate impacts on primary endpoint effect size based on gaps in follow-up, loss to follow-up, or consent withdrawal.

### **Section Summary: Cardiovascular Disease**

A Cochrane review of several RCTs of chelation therapy did not show sufficient evidence to draw conclusions about the efficacy of EDTA chelation therapy compared to placebo. A 2022 systematic review included similar RCTs and numerous observational trials but did not perform meta-analysis on clinical outcomes. The TACT RCT included in systematic reviews has significant limitations, including a high dropout rate with differential dropout between groups, but reported that cardiovascular events were reduced in patients treated with chelation therapy. This effect was greater among patients with diabetes and post-anterior myocardial infarction. In 2025, findings from the TACT2 RCT failed to replicate the findings from the original TACT study among

individuals with diabetes and a previous myocardial infarction at least 6 months prior to recruitment.

### **Autism Spectrum Disorder**

Based on symptom similarities between mercury poisoning and autism spectrum disorder, Bernard et al (2001) hypothesized a link between environmental mercury and autism.<sup>19</sup> This theory was rejected by Nelson and Bauman (2003), who found that many characteristics of mercury poisoning, such as ataxia, constricted visual fields, peripheral neuropathy, hypertension, skin eruption, and thrombocytopenia, are never seen in autistic children.<sup>20</sup> A meta-analysis by Ng et al (2007) concluded that there was no association between mercury poisoning and autism.<sup>21</sup>

### **Clinical Context and Therapy Purpose**

The purpose of chelation therapy is to provide a treatment option that is an alternative to or an improvement on existing therapies for individuals with autism spectrum disorder.

The following PICO was used to select literature to inform this review.

#### ***Populations***

The population of interest is individuals with autism spectrum disorder.

#### ***Interventions***

The intervention of interest is chelation therapy.

#### ***Comparators***

The comparator of interest is standard medical care without chelation therapy.

#### ***Outcomes***

The outcomes of interest are symptoms, change in disease status, morbid events, functional outcomes, health status measures, quality of life, and treatment-related morbidity.

### **Study Selection Criteria**

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Studies with duplicative or overlapping populations were excluded.

## **REVIEW OF EVIDENCE**

### **Observational Studies**

Rossignol et al (2009) published a systematic review of novel and emerging treatments for autism and identified no controlled studies.<sup>22</sup> Rossignol et al (2009) stated that case series had suggested a potential role for chelation in treating some autistic people with known elevated heavy metal levels, but this possibility needed further investigation in controlled studies.

**Section Summary: Autism Spectrum Disorder**

There is a lack of controlled studies on how chelation therapy affects health outcomes in patients with autism.

**DIABETES****Clinical Context and Therapy Purpose**

The purpose of chelation therapy is to provide a treatment option that is an alternative to or an improvement on existing therapies for individuals with diabetes.

The following PICO was used to select literature to inform this review.

***Populations***

The population of interest is individuals with diabetes.

***Interventions***

The intervention of interest is chelation therapy.

***Comparators***

The comparator of interest is standard medical care without chelation therapy.

***Outcomes***

The outcomes of interest are symptoms, change in disease status, morbid events, functional outcomes, health status measures, quality of life, and treatment-related morbidity.

**Study Selection Criteria**

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Studies with duplicative or overlapping populations were excluded.

**REVIEW OF EVIDENCE****RANDOMIZED CONTROLLED TRIALS****Cardiovascular Disease in Patients With Diabetes**

A trial by Cooper et al (2009) in New Zealand evaluated the effect of copper chelation using oral trientine on left ventricular hypertrophy in 30 patients with type 2 diabetes.<sup>23</sup> Twenty-one (70%) of 30 participants completed 12 months of follow-up. At 12 months, there was a significantly greater reduction in left ventricular mass indexed to body surface area in the active treatment group (-10.6 g/m<sup>2</sup>) than in the placebo group (-0.1 g/m<sup>2</sup>; p=.01). The trial was limited by small sample size and high dropout rate.

Escolar et al (2014) published results of a prespecified subgroup analysis of diabetic patients in TACT.<sup>24</sup> In this trial (also discussed above), there was a statistically significant interaction between treatment (EDTA or placebo) and presence of diabetes. Among 538 (31% of the trial sample) self-reported diabetic patients, those randomized to EDTA had a 39% reduced risk of the primary composite outcome (ie, death from any cause, reinfarction, stroke, coronary revascularization, or hospitalization for angina at 5 years) compared with placebo (HR, 0.61; 95% CI, 0.45 to 0.83;  $p=.02$ ); among 1170 nondiabetic patients, risk of the primary outcome did not differ statistically between treatment groups (HR, 0.96; 95% CI, 0.77 to 1.20;  $p=.73$ ).<sup>11</sup> For the subsequent subgroup analysis, the definition of diabetes was broadened to include self-reported diabetes, use of oral or insulin treatment for diabetes, or fasting blood glucose of 126 mg/dL or more at trial entry. Of 1708 patients in TACT, 633 (37%) had diabetes by this definition: 322 were randomized to EDTA and 311 to placebo. Compared with all other trial participants, this subgroup of diabetic patients had higher body mass index, fasting blood glucose, and prevalence of heart failure, stroke, hypertension, peripheral artery disease, and hypercholesterolemia. Within this subgroup, baseline characteristics were similar between treatment groups. With approximately 5 years of follow-up, the primary composite endpoint occurred in 25% of the EDTA group and 38% of the placebo group (adjusted HR, 0.59; 99.4% CI, 0.39 to 0.88;  $p=.002$ ). In adjusted analysis of the individual components of the primary endpoint, there were no statistically significant differences between treatment groups. Thirty-six adverse events attributable to the study drug led to trial withdrawal (16 in the EDTA group vs. 20 in the placebo group).

Several additional post-hoc analyses of TACT examined outcomes in patients with diabetes. Ujueta et al (2020) reported outcomes in 162 post-myocardial infarction patients with diabetes mellitus and peripheral artery disease.<sup>25</sup> The analysis showed that chelation therapy was associated with a significant reduction in the composite primary endpoint compared with placebo (HR, 0.52; 95% CI, 0.30 to 0.92;  $p=.0069$ ). Escolar et al (2020) performed a sub-analysis of diabetes mellitus patients included in TACT ( $n=633$ ) to determine the association between glucose lowering therapy and outcomes.<sup>26</sup> Chelation therapy was associated with a lower frequency of the primary outcome compared with placebo in patients on insulin ( $n=162$ ; 26% vs. 48%; HR, 0.42; 95% CI, 0.25 to 0.74), but not in patients on oral glucose-lowering therapy or no glucose-lowering therapy.

The TACT2 RCT replicated the TACT study design but restricted enrollment to individuals with diabetes.<sup>18</sup> Results from the TACT2 RCT, summarized in the cardiovascular section above, failed to replicate the original TACT study findings.

### **Diabetic Nephropathy**

Chen et al (2012) conducted a single-blind RCT assessing the effects of chelation therapy on the progression of diabetic nephropathy in Chinese patients with high-normal lead levels.<sup>27</sup> Fifty patients with diabetes, high-normal body lead burden (80 to 6000  $\mu\text{g}$ ), and serum creatinine of 3.8 mg/dL or lower were included. Baseline mean blood lead levels were 6.3  $\mu\text{g}/\text{dL}$  in the treatment group and 7.1  $\mu\text{g}/\text{dL}$  in the control group; baseline mean body lead burden was 151  $\mu\text{g}$  in the treatment group and 142  $\mu\text{g}$  in the control group. According to the U.S. Occupational and Health Safety Administration, the maximum acceptable blood lead level in adults is 40  $\mu\text{g}/\text{dL}$ .<sup>28</sup> Patients were randomized to 3 months of calcium disodium EDTA or to placebo. During 24 months of treatment follow-up, patients in the chelation group received additional chelation treatments as needed (ie, for serum creatinine level above pretreatment levels or body lead

burden  $>60 \mu\text{g}$ ), and patients in the placebo group continued to receive placebo medication. All patients completed the 27-month trial. The primary outcome was change in estimated glomerular filtration rate. Mean yearly rate of decrease in estimated glomerular filtration rate was 5.6 mL/min/1.73 m<sup>2</sup> in the chelation group and 9.2 mL/min/1.73 m<sup>2</sup> in the control group, a statistically significant difference ( $p=.04$ ). The secondary endpoint was the number of patients in whom the baseline serum creatinine doubled or who required renal replacement therapy. Nine (36%) patients in the treatment group and 17 (68%) in the control group attained the secondary endpoint, a statistically significant difference ( $p=.02$ ). There were no reported adverse events of chelation therapy during the trial.

### **Section Summary: Diabetes**

Two small RCTs with limitations and the failed TACT2 RCT represent insufficient evidence that chelation therapy is effective for treating cardiovascular disease in patients with diabetes. One small, single-blind RCT is insufficient evidence that chelation therapy is effective for treating diabetic nephropathy in patients with high-normal lead levels. Additional RCTs with larger numbers of patients that report health outcomes (eg, cardiovascular events, end-stage renal disease, mortality) are needed.

## **PARKINSON DISEASE**

### **Clinical Context and Therapy Purpose**

The purpose of chelation therapy is to provide a treatment option that is an alternative to or an improvement on existing therapies for individuals with Parkinson disease.

The following PICO was used to select literature to inform this review.

### ***Populations***

The population of interest is individuals with Alzheimer disease.

### ***Interventions***

The intervention of interest is chelation therapy.

### ***Comparators***

The comparator of interest is standard medical care without chelation therapy.

### ***Outcomes***

The outcomes of interest are symptoms, change in disease status, morbid events, functional outcomes, health status measures, quality of life, and treatment-related morbidity.

### **Study Selection Criteria**

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Studies with duplicative or overlapping populations were excluded.

## Review of Evidence

Iron chelation therapy is being investigated for Parkinson disease<sup>29,30</sup>, and endotoxemia.<sup>31</sup> Devos et al (2022) conducted a phase 2, randomized, double-blind, 36-week trial in 372 patients with newly diagnosed Parkinson disease.<sup>32</sup> Patients randomized to iron chelation with deferiprone had worse outcomes than those treated with placebo, with 22% of deferiprone-treated patients requiring initiation of dopaminergic therapy versus 2.7% of those treated with placebo. In addition, scores on the Unified Parkinson's Disease Rating Scale were worse with deferiprone, worsening by 15.6 points from baseline compared with 6.3 points in the placebo group (difference, 9.3 points; 95% CI, 6.3 to 12.2;  $p < .001$ ). In 2025, Devos and coworkers published findings from two phase 2 multicenter studies, SKY and EMBARK.<sup>33</sup> Patients on stable dopaminergic therapy were randomized 1:1 to one of four dosage cohorts of deferiprone for 9 months. EMBARK participants received a 15 mg/kg dose twice-daily, including patients on stable dopaminergic therapy or treatment-naïve individuals. In SKY, motor benefit was not seen when deferiprone was combined with L-dopa, and in EMBARK patients not treated with L-dopa, exposure to deferiprone worsened symptoms.

## Section Summary: Parkinson Disease

Several phase 2 multicenter studies have failed to demonstrate motor benefits from the iron chelation agent deferiprone in individuals with Parkinson disease.

## OTHER POTENTIAL INDICATIONS: MULTIPLE SCLEROSIS AND ARTHRITIS

### Clinical Context and Therapy Purpose

The purpose of chelation therapy is to provide a treatment option that is an alternative to or an improvement on existing therapies for individuals with multiple sclerosis (MS) or arthritis.

The following PICO was used to select literature to inform this review.

### Populations

The population of interest is individuals with MS or arthritis.

### Interventions

The intervention of interest is chelation therapy.

### Comparators

The comparator of interest is standard medical care without chelation therapy.

### Outcomes

The outcomes of interest are symptoms, change in disease status, morbid events, functional outcomes, health status measures, quality of life, and treatment-related morbidity.

### Study Selection Criteria

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.

- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Studies with duplicative or overlapping populations were excluded.

### **Review of Evidence**

No RCTs or other controlled trials evaluating the safety and efficacy of chelation therapy for MS or arthritis were identified.

### **SUPPLEMENTAL INFORMATION**

The purpose of the following information is to provide reference material. Inclusion does not imply endorsement or alignment with the evidence review conclusions.

### **Practice Guidelines and Position Statements**

Guidelines or position statements will be considered for inclusion in 'Supplemental Information if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

### **American Heart Association and American College of Cardiology**

In 2016, the American College of Cardiology (ACC) and the American Heart Association (AHA) published a joint guideline on the management of patients with lower extremity peripheral artery disease, which stated that chelation therapy (eg, ethylenediaminetetraacetic acid) is not beneficial for the treatment of claudication.<sup>34</sup>

In 2014, the ACC and AHA published a focused update of the guideline for the management of stable ischemic heart disease, in conjunction with the American Association for Thoracic Surgery, Preventative Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons. This update included a revised recommendation on chelation therapy stating that the "usefulness of chelation therapy is uncertain for reducing cardiovascular events in patients with stable IHD."<sup>35</sup> Compared to the original publication of this guideline in 2012, the recommendation was upgraded from a class III (no benefit) to class IIb (benefit  $\geq$  risk), and the level of evidence from C (only consensus expert opinion, case studies, or standard of care) to B (data from a single randomized trial or nonrandomized studies).<sup>36</sup> A 2023 guideline from these organizations on managing chronic coronary disease provided comments about chelation therapy but no formal recommendations.<sup>37</sup>

### **American Heart Association**

In 2023, the AHA published a scientific statement about the cardiovascular risk of contaminant metals.<sup>38</sup> The authors cited the TACT trial findings of a reduced relative risk of cardiovascular events among patients who received chelation therapy, but also noted that TACT did not evaluate metal levels. Results of the TACT2 trial were not yet available at the time of publication.

### **American Academy of Pediatrics**

In 2019, the American Academy of Pediatrics published guidance for the management of children with autism spectrum disorder. The guidance cautioned against the use of chelation therapy due to safety concerns and lack of supporting efficacy data.<sup>39</sup>

**U.S. Preventive Services Task Force Recommendations**

Not applicable.

**Ongoing and Unpublished Clinical Trials**

Some currently unpublished trials that might influence this review are listed in Table 4.

**Table 4. Summary of Key Trials**

<b>NCT No.</b>	<b>Trial Name</b>	<b>Planned Enrollment</b>	<b>Completion Date</b>
<i>Ongoing</i>			
NCT03982693	Trial to Assess Chelation Therapy in Critical Limb Ischemia (TACT3a)	50	Jul 2025
NCT03754725	A Phase 1/2a Exploratory Clinical Trial to Evaluate the Safety of Oral Deferiprone (14 Days) Including Its Effect on Decreasing the Content of Iron in Subjects With Aneurysmal Subarachnoid Hemorrhage (aSAH) sIRB	66	Apr 2026
NCT06763055	The Fifth Intensive Preventing Secondary Injury in Acute Cerebral Haemorrhage Trial Within ACT-GLOBAL (INTERACT5)	2000	Jan 2028

NCT: national clinical trial.

<sup>a</sup> Denotes industry-sponsored or cosponsored trial.

**CODING**

**The following codes for treatment and procedures applicable to this policy are included below for informational purposes. This may not be a comprehensive list of procedure codes applicable to this policy.**

**Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.**

**The code(s) listed below are medically necessary ONLY if the procedure is performed according to the "Policy" section of this document.**

<b>CPT/HCPCS</b>	
96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour
96366	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure)
96374	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug
J0470	Injection, dimercaprol, per 100 mg
J0600	Injection, edetate calcium disodium, up to 1,000 mg
J0895	Injection, deferoxamine mesylate, 500 mg
J3520	Edetate disodium, per 150 mg
M0300	IV chelation therapy (chemical endarterectomy)
S9355	Home infusion therapy, chelation therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem

<b>REVISIONS</b>	
11-19-2012	Policy added to the bcbsks.com web site. Effective for Institutional providers 12-19-2012.
03-31-2014	Description section updated In Policy section: <ul style="list-style-type: none"> <li>▪ Added to A 4 "and due to nontransfusion-dependent thalassemia (NDDT)" to read, "4. treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) and due to nontransfusion-dependent thalassemia (NDDT)"</li> <li>▪ Added to B 1 "secondary prevention in patients with myocardial infarction" to read, "1. atherosclerosis (i.e., coronary artery disease, secondary prevention in patients with myocardial infarction, or peripheral vascular disease)"</li> </ul> Rationale section updated In Coding section: <ul style="list-style-type: none"> <li>▪ Removed ICD-9 Diagnoses Codes: 427.9, 440.0-440.9</li> <li>▪ Added ICD-10 Diagnoses Codes</li> </ul> References updated
08-19-2016	Published 07-20-2016. Effective 08-19-2016

<b>REVISIONS</b>	
	Policy title changed to "Chelation Therapy for Off-Label Uses" from "Chelation Therapy"
	Description section updated
	In Policy section: <ul style="list-style-type: none"> <li>▪ Removed the following from the Policy language and restated the FDA approved indications in Policy Guidelines: "Chelation therapy may be considered medically necessary in the treatment of each of the following conditions: <ol style="list-style-type: none"> <li>1. extreme conditions of metal toxicity</li> <li>2. treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) and due to non-transfusion-dependent thalassemia (NTDT) (NDTD)</li> <li>3. Wilson's disease (hepatolenticular degeneration)</li> <li>4. lead poisoning</li> <li>5. control of ventricular arrhythmias or heart block associated with digitalis toxicity</li> <li>6. emergency treatment of hypercalcemia"</li> </ol> <ul style="list-style-type: none"> <li>▪ In policy statement removed "Other" and added "Off-label" and "(see Policy Guidelines section for uses approved by the Food and Drug Administration)" to read "Off-label applications of chelation therapy (see Policy Guidelines section for uses approved by the Food and Drug Administration) are considered experimental / investigational, including, but not limited to:"</li> <li>▪ Removed Off-label indication "hypoglycemia"</li> <li>▪ Added Policy Guidelines to read: <ol style="list-style-type: none"> <li>" 1. A number of indications for chelation therapy have received Food and Drug Administration (FDA) approval and for which chelation therapy is considered standard of care treatment. They include: <ol style="list-style-type: none"> <li>a. extreme conditions of metal toxicity</li> <li>b. treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) and due to non-transfusion-dependent thalassemia (NTDT)</li> <li>c. Wilson disease (hepatolenticular degeneration)</li> <li>d. lead poisoning</li> <li>e. control of ventricular arrhythmias or heart block associated with digitalis toxicity</li> <li>f. emergency treatment of hypercalcemia</li> </ol> </li> <li>2. For items 1 e and 1 f, most patients should be treated with other modalities. Digitalis toxicity is currently treated in most patients with Fab monoclonal antibodies. FDA removed the approval for NaEDTA as chelation therapy due to safety concerns and recommended that other chelators be used. This was the most common chelation agent used to treat digitalis toxicity and hypercalcemia.</li> <li>3. Suggested toxic or normal levels of select heavy metals are listed in Appendix Table 1."</li> </ol> </li> </ul> </li> </ul>
	Rationale section updated
	In Coding section: <ul style="list-style-type: none"> <li>▪ CPT Code Correction: Replaced 96375 with 96374</li> <li>▪ Removed ICD codes and replaced with the phrase "Experimental / Investigational for all diagnoses related to this medical policy."</li> </ul>
	References updated
	Added "Appendix Table 1. Toxic or Normal Concentrations of Heavy Metals"
04-11-2018	Description section updated
	Revision section updated
	References updated
	Appendix updated
05-21-2019	Description section updated
	In Policy section:

<b>REVISIONS</b>	
	<ul style="list-style-type: none"> <li>▪ Updated Policy Guideline 1 b changing "and" to "or" to read "treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) or due to non-transfusion-dependent thalassemia (NTDT)"</li> </ul>
	Revision section updated
	References updated
04-16-21	Description section updated
	Revision section updated
	References updated
04-08-2022	Updated Description Section
	Updated Rationale Section
	Updated References Section
03-28-2023	Updated Description Section
	Updated Policy Guidelines <ul style="list-style-type: none"> <li>▪ Removed policy guideline C that referenced the appendix "Suggested toxic or normal levels of select heavy metals are listed in Appendix Table 1."</li> </ul>
	Updated Rationale Section
	Updated Coding Section <ul style="list-style-type: none"> <li>▪ Removed ICD-10 Diagnoses box</li> </ul>
	Updated References Section
	Removed Appendix Section
03-26-2024	Updated Description Section
	Updated Rationale Section
	Updated References Section
03-27-2025	Updated Description Section
	Updated Rationale Section
	Updated References Section
04-14-2026	Updated Description Section
	Updated References Section
	Updated References Section

## REFERENCES

1. Centers for Disease Control and Prevention (CDC). Deaths associated with hypocalcemia from chelation therapy--Texas, Pennsylvania, and Oregon, 2003-2005. *MMWR Morb Mortal Wkly Rep.* Mar 03 2006; 55(8): 204-7. PMID 16511441
2. Food and Drug Administration. Hospira, Inc., et al.; Withdrawal of Approval of One New Drug Application and Two Abbreviated New Drug Application. *Federal Register.* 2008;73(113):33440-33441.
3. Sampson E, Jenagaratnam L, McShane R. Metal protein attenuating compounds for the treatment of Alzheimer's disease. *Cochrane Database Syst Rev.* Jan 23 2008; (1): CD005380. PMID 18254079
4. Ritchie CW, Bush AI, Mackinnon A, et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. *Arch Neurol.* Dec 2003; 60(12): 1685-91. PMID 14676042
5. Sampson EL, Jenagaratnam L, McShane R. Metal protein attenuating compounds for the treatment of Alzheimer's dementia. *Cochrane Database Syst Rev.* Feb 21 2014; 2014(2): CD005380. PMID 24563468

6. Sampson EL, Jenagaratnam L, McShane R. Metal protein attenuating compounds for the treatment of Alzheimer's dementia. *Cochrane Database Syst Rev.* May 16 2012; 5(5): CD005380. PMID 22592705
7. Lannfelt L, Blennow K, Zetterberg H, et al. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. *Lancet Neurol.* Sep 2008; 7(9): 779-86. PMID 18672400
8. Ayton S, Barton D, Brew B, et al. Deferiprone in Alzheimer Disease: A Randomized Clinical Trial. *JAMA Neurol.* Jan 01 2025; 82(1): 11-18. PMID 39495531
9. Ravalli F, Vela Parada X, Ujueta F, et al. Chelation Therapy in Patients With Cardiovascular Disease: A Systematic Review. *J Am Heart Assoc.* Mar 15 2022; 11(6): e024648. PMID 35229619
10. Villarruz-Sulit MV, Forster R, Dans AL, et al. Chelation therapy for atherosclerotic cardiovascular disease. *Cochrane Database Syst Rev.* May 05 2020; 5(5): CD002785. PMID 32367513
11. Lamas GA, Goertz C, Boineau R, et al. Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial. *JAMA.* Mar 27 2013; 309(12): 1241-50. PMID 23532240
12. Mark DB, Anstrom KJ, Clapp-Channing NE, et al. Quality-of-life outcomes with a disodium EDTA chelation regimen for coronary disease: results from the trial to assess chelation therapy randomized trial. *Circ Cardiovasc Qual Outcomes.* Jul 2014; 7(4): 508-16. PMID 24987051
13. Lamas GA, Boineau R, Goertz C, et al. EDTA chelation therapy alone and in combination with oral high-dose multivitamins and minerals for coronary disease: The factorial group results of the Trial to Assess Chelation Therapy. *Am Heart J.* Jul 2014; 168(1): 37-44.e5. PMID 24952858
14. Lewis EF, Ujueta F, Lamas GA, et al. Differential Outcomes With Edetate Disodium-Based Treatment Among Stable Post Anterior vs. Non-Anterior Myocardial Infarction Patients. *Cardiovasc Revasc Med.* Nov 2020; 21(11): 1389-1395. PMID 32303436
15. Nissen SE. Concerns about reliability in the Trial to Assess Chelation Therapy (TACT). *JAMA.* Mar 27 2013; 309(12): 1293-4. PMID 23532246
16. Maron DJ, Hlatky MA. Trial to Assess Chelation Therapy (TACT) and equipoise: When evidence conflicts with beliefs. *Am Heart J.* Jul 2014; 168(1): 4-5. PMID 24952853
17. Lamas GA, Anstrom KJ, Navas-Acien A, et al. The trial to assess chelation therapy 2 (TACT2): Rationale and design. *Am Heart J.* Oct 2022; 252: 1-11. PMID 35598636
18. Lamas GA, Anstrom KJ, Navas-Acien A, et al. Edetate Disodium-Based Chelation for Patients With a Previous Myocardial Infarction and Diabetes: TACT2 Randomized Clinical Trial. *JAMA.* Sep 10 2024; 332(10): 794-803. PMID 39141382
19. Bernard S, Enayati A, Redwood L, et al. Autism: a novel form of mercury poisoning. *Med Hypotheses.* Apr 2001; 56(4): 462-71. PMID 11339848
20. Nelson KB, Bauman ML. Thimerosal and autism?. *Pediatrics.* Mar 2003; 111(3): 674-9. PMID 12612255
21. Ng DK, Chan CH, Soo MT, et al. Low-level chronic mercury exposure in children and adolescents: meta-analysis. *Pediatr Int.* Feb 2007; 49(1): 80-7. PMID 17250511
22. Rossignol DA. Novel and emerging treatments for autism spectrum disorders: a systematic review. *Ann Clin Psychiatry.* 2009; 21(4): 213-36. PMID 19917212

23. Cooper GJ, Young AA, Gamble GD, et al. A copper(II)-selective chelator ameliorates left-ventricular hypertrophy in type 2 diabetic patients: a randomised placebo-controlled study. *Diabetologia*. Apr 2009; 52(4): 715-22. PMID 19172243
24. Escolar E, Lamas GA, Mark DB, et al. The effect of an EDTA-based chelation regimen on patients with diabetes mellitus and prior myocardial infarction in the Trial to Assess Chelation Therapy (TACT). *Circ Cardiovasc Qual Outcomes*. Jan 2014; 7(1): 15-24. PMID 24254885
25. Ujueta F, Arenas IA, Escolar E, et al. The effect of EDTA-based chelation on patients with diabetes and peripheral artery disease in the Trial to Assess Chelation Therapy (TACT). *J Diabetes Complications*. Jul 2019; 33(7): 490-494. PMID 31101487
26. Escolar E, Ujueta F, Kim H, et al. Possible differential benefits of edetate disodium in post-myocardial infarction patients with diabetes treated with different hypoglycemic strategies in the Trial to Assess Chelation Therapy (TACT). *J Diabetes Complications*. Aug 2020; 34(8): 107616. PMID 32446881
27. Chen KH, Lin JL, Lin-Tan DT, et al. Effect of chelation therapy on progressive diabetic nephropathy in patients with type 2 diabetes and high-normal body lead burdens. *Am J Kidney Dis*. Oct 2012; 60(4): 530-8. PMID 22721929
28. U.S Food and Drug Administration. FDA warns consumers about potential health risks from using Thorne Research's Captomer products. 2014 June 12; <https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-consumers-about-potential-health-risks-using-thorne-researchs-captomer-products>. Accessed December 12, 2025.
29. Weinreb O, Mandel S, Youdim MBH, et al. Targeting dysregulation of brain iron homeostasis in Parkinson's disease by iron chelators. *Free Radic Biol Med*. Sep 2013; 62: 52-64. PMID 23376471
30. Grolez G, Moreau C, Sablonnière B, et al. Ceruloplasmin activity and iron chelation treatment of patients with Parkinson's disease. *BMC Neurol*. May 06 2015; 15: 74. PMID 25943368
31. van Eijk LT, Heemskerk S, van der Pluijm RW, et al. The effect of iron loading and iron chelation on the innate immune response and subclinical organ injury during human endotoxemia: a randomized trial. *Haematologica*. Mar 2014; 99(3): 579-87. PMID 24241495
32. Devos D, Labreuche J, Rascol O, et al. Trial of Deferiprone in Parkinson's Disease. *N Engl J Med*. Dec 01 2022; 387(22): 2045-2055. PMID 36449420
33. Devos D, Rascol O, Meissner WG, et al. Therapeutic modalities of deferiprone in Parkinson's disease: SKY and EMBARK studies. *J Parkinsons Dis*. Feb 2025; 15(1): 72-86. PMID 39973479
34. Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. Mar 21 2017; 135(12): e726-e779. PMID 27840333
35. Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. *J Am Coll Cardiol*. Nov 04 2014; 64(18): 1929-49. PMID 25077860

36. Qaseem A, Fihn SD, Dallas P, et al. Management of stable ischemic heart disease: summary of a clinical practice guideline from the American College of Physicians/American College of Cardiology Foundation/American Heart Association/American Association for Thoracic Surgery/Preventive Cardiovascular Nurses Association/Society of Thoracic Surgeons. *Ann Intern Med.* Nov 20 2012; 157(10): 735-43. PMID 23165665
37. Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. *Circulation.* Aug 29 2023; 148(9): e9-e119. PMID 37471501
38. Lamas GA, Bhatnagar A, Jones MR, et al. Contaminant Metals as Cardiovascular Risk Factors: A Scientific Statement From the American Heart Association. *J Am Heart Assoc.* Jul 04 2023; 12(13): e029852. PMID 37306302
39. Hyman SL, Levy SE, Myers SM, et al. Identification, Evaluation, and Management of Children With Autism Spectrum Disorder. *Pediatrics.* Jan 2020; 145(1). PMID 31843864
40. Centers for Medicare & Medicaid Services (CMS). National Coverage Determination (NCD) for CHELATION THERAPY for Treatment of Atherosclerosis (20.21). n.d.; <https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=86>. Accessed December 12, 2025.
41. Centers for Medicare & Medicaid Services (CMS). National Coverage Determination (NCD) for Ethylenediamine- Tetra-Acetic (EDTA) CHELATION THERAPY for Treatment of Atherosclerosis (20.22). n.d.; <https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=146&ncdver=1&bc=AAAAQAAAAAAA&>. Accessed December 11, 2025.
42. Centers for Disease Control and Prevention (CDC). Childhood Lead Poisoning Prevention. August 21, 2025; [https://www.cdc.gov/lead-prevention/about/index.html?CDC\\_AAref\\_Val=https://www.cdc.gov/nceh/lead/ACCLPP/bl\\_ood\\_lead\\_levels.htm](https://www.cdc.gov/lead-prevention/about/index.html?CDC_AAref_Val=https://www.cdc.gov/nceh/lead/ACCLPP/bl_ood_lead_levels.htm). Accessed December 11, 2025.
43. Centers for Disease Control and Prevention (CDC). Very high blood lead levels among adults - United States, 2002-2011. *MMWR Morb Mortal Wkly Rep.* Nov 29 2013; 62(47): 967-71. PMID 24280917
44. Agency for Toxic Substances and Disease Registry. Toxicological profile for mercury. 2024; <https://www.atsdr.cdc.gov/ToxProfiles/tp46.pdf>. Accessed December 12, 2025.
45. Adal A. Medscape. Heavy metal toxicity. Updated 2025; <http://emedicine.medscape.com/article/814960-overview>. Accessed December 12, 2025.
46. Kempson IM, Lombi E. Hair analysis as a biomonitor for toxicology, disease and health status. *Chem Soc Rev.* Jul 2011; 40(7): 3915-40. PMID 21468435